Novartis generics arm files for MS biosimilar, challenging Biogen; Pluristem shortens name
Novartis’ generics arm Sandoz said it has submitted applications for a multiple sclerosis and Crohn’s disease biosimilar.
The drug is a biosimilar for Biogen’s Tysabri …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
